Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details)

v3.21.2
Schedule of Accrued Expenses (Details) - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll and incentives $ 619,000 $ 1,094,000
General and administrative expenses 249,000 280,000
Research and development expenses 1,055,000 778,000
Deferred revenue and other deferred liabilities * [1] 840,000 643,000
Total $ 2,762,736 $ 2,795,329
[1] At June 30, 2021, there was an approximately $807 thousand deferred liability under the Cystic Fibrosis Foundation (“CFF”) agreement and approximately $33 thousand in deferred revenue related to the Genentech Agreement. At December 31, 2020, there was an approximately $577 thousand deferred liability under the CFF Agreement and approximately $67 thousand in deferred revenue related to the Genentech Agreement. (See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements).